PLK1 and neoplasm: Rosenblum et al. reported a single intracerebral injection of CRISPR-LNPs against PLK1 (sgPLK1-cLNPs) into metastatic orthotopic glioblastoma enhanced the in vivo gene editing specificity up to ~70%, which inhibited tumor growth by 50%, induced tumor cell apoptosis, and enhanced survival by 30% (87).